EODData

FRA, 9EP: Enanta Pharmaceuticals Inc

27 Mar 2026
LAST:

10.40

CHANGE:
 0.20
OPEN:
10.70
HIGH:
10.70
ASK:
0.00
VOLUME:
0
CHG(%):
1.89
PREV:
10.60
LOW:
10.40
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Mar 2610.7010.7010.4010.400
26 Mar 2610.3011.0010.3010.60300
25 Mar 2610.2010.8010.2010.30300
24 Mar 2610.8010.8010.2010.20300
23 Mar 2610.5010.9010.5010.70300
20 Mar 2611.0011.1010.6010.60150
19 Mar 2610.8011.0010.8011.000
18 Mar 2611.4011.4010.8010.800
17 Mar 2611.0011.5011.0011.300
16 Mar 2611.0011.1010.9011.000

PROFILE

Name:Enanta Pharmaceuticals Inc
About:Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:4 Kingsbury Avenue, Watertown, MA, United States, 02472
Website:https://www.enanta.com
ISIN:US29251M1062
LEI:529900SSN4DODDQSN594

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:-3.41 
Forward P/E:-2.39 
PEG Ratio:0.09 
Price to Sales:5.87 
Price to Book:5.10 
Profit Margin:-1.25 
Operating Margin:-1.22 
Return on Assets:-0.16 
Return on Equity:-0.85 
Revenue:55.49M 
Shares:21.38M 
Market Cap:222.33M 

TECHNICAL INDICATORS

MA5:10.440.4%
MA10:10.692.8%
MA20:11.298.6%
MA50:11.238.0%
MA100:11.238.0%
MA200:9.1613.6%
STO9:15.38 
STO14:11.11 
RSI14:34.15 
WPR14:-88.89 
MTM14:-1.30
ROC14:-0.11 
ATR:0.47 
Week High:11.106.7%
Week Low:10.202.0%
Month High:13.3027.9%
Month Low:10.2013.6%
Year High:14.2036.5%
Year Low:3.61187.8%
Volatility:41.45